New Desensitisation Strategy: A Case Series of Daratumumab in Highly Sensitised Kidney Transplant Candidates (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1210; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "2. Synergistic immunomodulation: Combination therapy (Rituximab & Daratumumab) targets both B cells & plasma cells,enhancing desensitization efficacy in highly sensitized recipients."
Clinical • Immunology • Infectious Disease • Transplantation
|
|
Vijay Kumar Sinha; Urvashi Khan
|